| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to a compound of general formula (I), or a pharmaceutically acceptable salt thereof. In formula (I) X 1 is CR 6 ; X 2 is CR 7 ; R 11 is (1) OR 1 or (2) NH 2 ; R 1 is (1) a hydrogen atom or (2) a C1-4 alkyl group; each R 2 and R 3 independently represents (1) a hydrogen atom or (2) a C1-4 alkyl group which can be substituted with a halogen atom, where R 2 and R 3 both can not simultaneously represent a hydrogen atom; each R 4 , R 5 , R 6 and R 7 independently represents (1) a hydrogen atom, (2) a halogen atom or (3) a C1-4 alkyl group, where R 4 and R 5 both can not simultaneously represent a hydrogen atom; Y is (1) -NH- or (2) a bond; R 8 is (1) a hydrogen atom or (2) a C1-4 alkyl group; R 9 represents (1) a cycle A, (2) C1-6 alkyl group, (3) -C1-4 alkylene-cycle A, (4) -cycle B-cycle C, (5) -cycle B-C1-4 alkylene -cycle C or (6) -cycle BO-cycle C, where alkyl group can be substituted with halogen atom. Cycle A is (1) C3-8 cycloalkane, (2) 3-8-member heterocycloalkane containing from one to three heteroatoms selected from oxygen and nitrogen atoms, (3) C3-12 monocyclic or bicyclic unsaturated carbocyclic ring or (4) 3–12-member monocyclic or bicyclic unsaturated heterocycle containing one to four heteroatoms selected from oxygen, nitrogen and sulfur atoms. Each cycle B and C independently represents (1) C3-8 cycloalkane, (2) 3–8-member heterocycloalkane, containing from one to three heteroatoms selected from oxygen and nitrogen atoms, (3) C3-7 monocyclic unsaturated carbocyclic ring or (4) 3–7-membered monocyclic unsaturated heterocycle containing one to three heteroatoms selected from oxygen, nitrogen and sulfur atoms. Each of cycles A, B and C can be independently substituted with one-five R 10 . Invention also relates to a method of preventing and/or treating a disease associated with KCNQ2-3 channel, use of the compound of formula (I) for preparing an agent for preventing and/or treating said disease and to a specific compound - 1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}urea. n n n n EFFECT: compounds can be used for preventing and/or treating a disease associated with KCNQ2-3 channel. n 14 cl, 5 tbl, 79 ex |